Cancers, Free Full-Text

Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.

Cancers, Free Full-Text

Free PSD Breast cancer awareness editable text effect

Noninvasive detection of any-stage cancer using free glycosaminoglycans

MD Anderson Cancer Center: Cancer Treatment & Cancer Research Hospital

American Cancer Society

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers, Breast Cancer Research

Harboring Hard and Soft Cells Lets Tumors Grow and Metastasize Simultaneously

Journal of Cancer Research and Clinical Oncology